Results 251 to 260 of about 2,675,396 (301)
Some of the next articles are maybe not open access.
Rheumatoid Arthritis — Anti-TNF
International Immunopharmacology, 2015This review will focus on the recent information and strategies now informing best use of TNF inhibitor therapy in RA. These issues include the role of TNFi therapy in early RA management, anti-drug antibodies in TNFi therapy, updates on safety and optimal dosage regimens in long term management.
Khaldoun, Chaabo, Bruce, Kirkham
openaire +2 more sources
Anti-TNFs in axial spondyloarthritis
Wiener Medizinische Wochenschrift, 2015Since there is no evidence regarding the efficacy of conventional synthetic disease modifying anti-rheumatic drugs in the improvement of axial spondyloarthritis (SpA), anti-tumor necrosis factors (anti-TNFs) are recommended if nonsteroidal anti-inflammatory drugs fail, or in case of high disease activity.
Roland, Kocijan +2 more
openaire +2 more sources
Safety of anti-TNF agents in pregnancy
Journal of Allergy and Clinical Immunology, 2021Inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis are associated with adverse pregnancy outcomes. Active maternal disease during pregnancy is associated with additional negative outcomes. Anti-TNF agents are effective treatments for inflammatory bowel disease, rheumatoid arthritis, ankylosing ...
Kara M, De Felice, Sunanda, Kane
openaire +2 more sources
Anti-TNFs: Originators and Biosimilars
Digestive Diseases, 2016In the last 20 years, the advent of anti-tumor necrosis factor alpha (TNFα) biologics has revolutionized the treatment of patients with inflammatory bowel disease (IBD) but the cost of biologic therapy now constitutes a large proportion of all healthcare expenditures. Patent expiration has sparked the healthcare industry's interest in the production of
openaire +2 more sources
Reumatología Clínica (English Edition), 2010
Tumor necrosis factor (TNF) is implicated in the control of tumoral growth in addition to the systemic inflammatory response. TNF blockage produces a comprensible reservation in patients with risk factors for cancer. No clear evidence for this came out from pre-clinical or clinical trials.
openaire +2 more sources
Tumor necrosis factor (TNF) is implicated in the control of tumoral growth in addition to the systemic inflammatory response. TNF blockage produces a comprensible reservation in patients with risk factors for cancer. No clear evidence for this came out from pre-clinical or clinical trials.
openaire +2 more sources
Anti‐TNF alpha medications and neuropathy
Journal of the Peripheral Nervous System, 2015AbstractWe studied the clinical, electrophysiological, and pathological features, outcome, and frequency of anti‐tumor necrosis factor alpha (a‐TNF) medications‐induced neuropathies (ATIN) in patients with inflammatory disorders. Of 2,017 patients treated with a‐TNF medication, 12 patients met our inclusion criteria for a prevalence of 0.60% and an ...
Tsouni P +6 more
openaire +3 more sources
Sepsis, 1999
Monoclonal antibodies to tumor necrosis factor alpha (TNF-α) and soluble receptor complexes comprising the extramembrane portion of the TNF receptor coupled with the Fc portion of the human IgG1 molecule have been utilized as therapies for severe sepsis and septic shock.
openaire +1 more source
Monoclonal antibodies to tumor necrosis factor alpha (TNF-α) and soluble receptor complexes comprising the extramembrane portion of the TNF receptor coupled with the Fc portion of the human IgG1 molecule have been utilized as therapies for severe sepsis and septic shock.
openaire +1 more source
The ‘Ideal' Anti-TNF Patient: Indications for Anti-TNF Therapy in Crohn's Disease
2015The introduction of anti-TNF monoclonal antibodies to the therapeutic arsenal has represented a major advance in the management of Crohn's disease (CD).
My-Linh Tran-Minh +2 more
openaire +1 more source
Anti-TNF in rheumatoid arthritis: an overview
Wiener Medizinische Wochenschrift, 2015Since the introduction of tumor necrosis factor (TNF)-α inhibitors, the treatment of rheumatoid arthritis (RA) has been revolutionized. The approach of targeting TNF-α has considerably improved the success in the treatment of RA. Over the last 3 decades five different TNF-α inhibitors have been administered: infliximab, etanercept, adalimumab ...
Helga, Radner, Daniel, Aletaha
openaire +2 more sources
Anti-TNF Therapeutics for the Treatment of Sarcoidosis
Immunotherapy, 2014Sarcoidosis is a systemic disease with an incidence of 1 to 40 per 100 000 persons per year. It predominantly affects people in the age of 20 to 40 years old. Disease course varies from mild self-limiting to chronic debilitating and life-threatening disease. Since the cause of sarcoidosis is unknown, curative therapy is not available. Immunosuppressive
Heleen A, Crommelin +5 more
openaire +2 more sources